Evidence map›Paper›PMID 30895564›Full record

ReviewPharmacoEconomics2019

Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Sabine E Grimm, Debra Fayter, Bram L T Ramaekers, Svenja Petersohn, Rob Riemsma, Nigel Armstrong, Xavier Pouwels, Willem Witlox, Caro Noake, Gillian Worthy and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in PharmacoEconomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sabine E GrimmDepartment of Clinical Epidemiology and Medical Technology Assessment, School for Public Health and Primary Care (CAPHRI), Maastricht University Medical Centre+, P. Debyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands. Sabine.grimm@mumc.nl.ORCID 0000-0002-2175-7999
Debra FayterKleijnen Systematic Reviews Ltd, 6 Escrick Business Park, Riccall Road, York, YO19 6FD, UK.
Bram L T RamaekersDepartment of Clinical Epidemiology and Medical Technology Assessment, School for Public Health and Primary Care (CAPHRI), Maastricht University Medical Centre+, P. Debyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands.
Svenja PetersohnDepartment of Clinical Epidemiology and Medical Technology Assessment, School for Public Health and Primary Care (CAPHRI), Maastricht University Medical Centre+, P. Debyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands.
Rob RiemsmaKleijnen Systematic Reviews Ltd, 6 Escrick Business Park, Riccall Road, York, YO19 6FD, UK.
Nigel ArmstrongKleijnen Systematic Reviews Ltd, 6 Escrick Business Park, Riccall Road, York, YO19 6FD, UK.
Xavier PouwelsDepartment of Clinical Epidemiology and Medical Technology Assessment, School for Public Health and Primary Care (CAPHRI), Maastricht University Medical Centre+, P. Debyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands.
Willem WitloxDepartment of Clinical Epidemiology and Medical Technology Assessment, School for Public Health and Primary Care (CAPHRI), Maastricht University Medical Centre+, P. Debyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands.
Caro NoakeKleijnen Systematic Reviews Ltd, 6 Escrick Business Park, Riccall Road, York, YO19 6FD, UK.
Gillian WorthyKleijnen Systematic Reviews Ltd, 6 Escrick Business Park, Riccall Road, York, YO19 6FD, UK.
Jos KleijnenKleijnen Systematic Reviews Ltd, 6 Escrick Business Park, Riccall Road, York, YO19 6FD, UK.
Manuela A JooreDepartment of Clinical Epidemiology and Medical Technology Assessment, School for Public Health and Primary Care (CAPHRI), Maastricht University Medical Centre+, P. Debyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands.

Funding

Department of Health 16/119/02
6 · The paper itself

Abstract

As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Merck Sharp & Dohme; MSD) of pembrolizumab (Keytruda

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCost-Benefit AnalysisHodgkin DiseaseHumansQuality-Adjusted Life YearsTechnology Assessment, BiomedicalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalpembrolizumab

Identifiers

PMID30895564
PMCPMC6713293

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.